(Q39396571)

11 September 2017

title

Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells (English)

1 reference

11 September 2017

1 reference

Tanja Wirth

1

1 reference

11 September 2017

Kianga Schmuck

series ordinal

2

1 reference

11 September 2017

Lutz F Tietze

series ordinal

3

1 reference

11 September 2017

Stephan A Sieber

series ordinal

4

1 reference

11 September 2017

language of work or name

English

0 references

publication date

14 February 2012

1 reference

Angewandte Chemie International Edition

11 September 2017

published in

0 references

volume

51

1 reference

11 September 2017

issue

12

1 reference

11 September 2017

page(s)

2874-2877

1 reference

Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Mechanisms of in situ activation for DNA-targeting antitumor agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Randomized, placebo-controlled, phase III surgical adjuvant clinical trial of megestrol acetate (Megace) in selected patients with malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Targeting: the ADEPT story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Probing the mechanism of action of potential anticancer agents at a molecular level using electrospray ionisation Fourier transform ion cyclotron resonance mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Activity-based probes as a tool for functional proteomic analysis of proteases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Mechanism-based profiling of enzyme families

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Natural products and their biological targets: proteomic and metabolomic labeling strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate-containing substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.201106334

21 January 2018

Identifiers

DOI

10.1002/ANIE.201106334

1 reference

11 September 2017

1 reference